Wang, J., Zhang, Q., Li, H., Tong, Z., Ouyang, Q., Li, H., Teng, Y., Wang, B., Sun, T., Wang, J., Li, W., Niu, Z., Li, H., Gong, C., Wang, S., Wang, X., Wu, X., Liu, N., Yu, G., Liu, F., Duan, X., Wang, S., Meng, Y., Wang, L., Xu, B. (2025). Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis. Nature Communications. https://doi.org/10.1038/s41467-025-58647-z